The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 22:27

UBS Group: The price reduction of the tenth round of collective procurement of Pharmaceuticals exceeded expectations, showing a cautious attitude towards the China generic drug market.

UBS Group released a research report stating that the tenth batch of national Pharmaceutical procurement in the mainland involves 62 types of Pharmaceuticals, with 385 products eligible for selection. Although the government has not disclosed the price reduction situation, according to Statistics, this time the reduction exceeds expectations, reaching 80% to 96%, and it is believed to be the largest reduction in history. The results of the Pharmaceutical procurement will be comprehensively implemented nationwide starting from April next year and will remain effective until the end of 2027. Overall, UBS Group believes that the results of the tenth batch of national Pharmaceutical procurement reflect China's tightening of the basic Medical Insurance Fund, and the government has also increased support for new drugs. Looking ahead, the bank holds a cautious attitude towards the prospects of China's generic drug market, and also anticipates.

AASTOCKSDec 19 09:49

3SBIO (1530.HK): Multiple products have renewed their medical insurance contracts, and the progress of the R&D pipeline is accelerating.

The 2024 National Medical Insurance Catalog results have been announced, with the company successfully renewing and adding multiple products. The renewed products include the company's key product, Tevazol (recombinant human thrombopoietin), and IniMon (HER2 monoclonal antibody), while the newly added product includes salt.

China Great WallDec 19 00:00

3SBio Cancels All Treasury Shares

MT NewswiresDec 18 19:50

3SBIO (01530.HK) canceled a total of 21.23 million shares of treasury stock.

Gelonghui, December 18, 3SBIO (01530.HK) announced that as of the date of this announcement, the company has repurchased a total of 21.23 million shares as treasury shares, accounting for approximately 0.89% of the total issued shares as of the date of this announcement (excluding treasury shares). These treasury shares have been canceled as of the date of this announcement.

Gelonghui FinanceDec 18 18:42

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16 14:21